Kyverna Therapeutics, Inc. Operating Cash Flow
Kyverna Therapeutics, Inc. (KYTX) reported Operating Cash Flow of -$81.90 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-11
- Kyverna Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$40.31M.
- Kyverna Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$41.60M.
- Kyverna Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$33.53M.
- Kyverna Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$43.32M.
- Kyverna Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2025 was -$153.71M.
- Kyverna Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2024 was -$114.25M.
- Kyverna Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2023 was -$52.41M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$40.31M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$81.90M 10-Q · filed 2026-08-11 | -$115.43M derived: sum of 3 quarters · filed 2026-08-11 | -$158.75M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | -$41.60M 10-Q · filed 2026-05-12 | -$75.12M derived: sum of 2 quarters · filed 2026-05-12 | -$118.44M derived: sum of 3 quarters · filed 2026-05-12 | -$150.39M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | -$33.53M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | -$76.85M derived: sum of 2 quarters · filed 2026-03-26 | -$108.80M derived: sum of 3 quarters · filed 2026-08-11 | -$153.71M 10-K · filed 2026-03-26 |
| 2025-09-30 | -$43.32M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$75.27M derived: sum of 2 quarters · filed 2026-08-11 | -$120.19M 10-Q · filed 2025-11-12 | -$157.25M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | -$31.95M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$76.86M 10-Q · filed 2026-08-11 | -$113.92M derived: sum of 3 quarters · filed 2026-08-11 | -$141.41M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | -$44.91M 10-Q · filed 2026-05-12 | -$81.98M derived: sum of 2 quarters · filed 2026-05-12 | -$109.47M derived: sum of 3 quarters · filed 2026-05-12 | -$133.64M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | -$37.06M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | -$64.55M derived: sum of 2 quarters · filed 2026-03-26 | -$88.72M derived: sum of 3 quarters · filed 2026-03-26 | -$114.25M 10-K · filed 2026-03-26 |
| 2024-09-30 | -$27.49M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$51.66M derived: sum of 2 quarters · filed 2025-11-12 | -$77.19M 10-Q · filed 2025-11-12 | -$95.75M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | -$24.18M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | -$49.70M 10-Q · filed 2025-08-12 | -$68.26M derived: sum of 3 quarters · filed 2025-08-12 | -$79.39M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | -$25.52M 10-Q · filed 2025-05-13 | -$44.09M derived: sum of 2 quarters · filed 2025-05-13 | -$55.22M derived: sum of 3 quarters · filed 2025-05-13 | -$66.48M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | -$18.56M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | -$29.70M derived: sum of 2 quarters · filed 2025-03-27 | -$40.95M derived: sum of 3 quarters · filed 2025-03-27 | -$52.41M 10-K · filed 2025-03-27 |
| 2023-09-30 | -$11.13M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | -$22.39M derived: sum of 2 quarters · filed 2024-11-13 | -$33.85M 10-Q · filed 2024-11-13 | |
| 2023-06-30 | -$11.26M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | -$22.71M 10-Q · filed 2024-08-12 | ||
| 2023-03-31 | -$11.46M 10-Q · filed 2024-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |